Related Experiment Videos
Immunohistological characterization of a Ewing's sarcoma case
S Lizard-Nacol1, F Mugneret, C Turc-Carel
1Laboratory of Cytogenetics, Faculté de Médecine, Dijon, France.
Cancer Detection and Prevention
|January 1, 1988
Summary
Histogenesis of Ewing sarcoma (ES) is unclear. Immunohistological analysis of ES with t(11;22) did not support mesenchymal or neuroectodermal origins, highlighting the chromosomal marker as the key diagnostic criterion.
Area of Science:
- Oncology
- Immunohistochemistry
- Molecular Genetics
Background:
- The cellular origin of Ewing sarcoma (ES), a rare bone and soft tissue cancer, remains debated.
- Previous hypotheses suggested mesenchymal or neuroectodermal origins for ES.
Purpose of the Study:
- To investigate the histogenesis of Ewing sarcoma (ES).
- To evaluate the validity of mesenchymal and neuroectodermal origin hypotheses for ES.
- To identify potential immunohistochemical markers for ES diagnosis.
Main Methods:
- Immunohistochemical analysis of frozen sections from an ES tumor with the t(11;22) chromosomal translocation.
- Utilized antibodies against monocyte/macrophage antigens (Leu M1, Leu M2, Leu M3, MO1) and neural markers (NSE, S-100, T4, HNK-1).
- Tested for HLA II antigen, B2-microglobulin, and intermediate filaments, including vimentin.
Main Results:
- No reactivity was observed with antibodies for monocyte/macrophage or neural lineage markers.
- Positive staining was detected for HLA II antigen and B2-microglobulin.
- Vimentin was the only intermediate filament identified within the tumor cells.
Conclusions:
- The immunohistochemical findings do not support either the mesenchymal or neuroectodermal origin hypotheses for this ES case.
- The specific chromosomal translocation t(11;22) remains the definitive diagnostic criterion for Ewing sarcoma in the absence of a clear immunological profile.